(AMRN) Amarin Corporation plc SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AMRN) Amarin Corporation plc Complete Analysis Pack
Make Confident Decisions Backed by Traceable Citations
This Amarin Corporation plc SWOT Analysis gives a concise, structured view of the company’s strengths, weaknesses, opportunities, and threats—useful for investing, strategy, or research. The page already includes a real preview of the actual analysis so you can judge style and substance before buying; purchase the full version to download the complete, ready-to-use report.
Strengths
VASCEPA, 1 prescription brand
VASCEPA is Amarin Corporation plc’s only prescription brand and the engine of its commercial business. It is used in adult patients with severe hypertriglyceridemia, so Amarin has a clear branded foothold in cardiovascular care. In 2024, Amarin reported about $220 million in net product revenue, with VASCEPA driving nearly all of it.
Cardiovascular-only focus
Amarin’s cardiovascular-only focus concentrates R&D and sales on one huge market: cardiovascular disease causes about 20.5 million deaths a year worldwide. That narrow scope can sharpen therapeutic expertise, tighten physician messaging, and keep the company’s brand clear around Vascepa and heart-risk care.
5-market international footprint
Amarin Corporation plc sells in 5 markets: the United States, Germany, Canada, Lebanon, and the UAE. That cuts reliance on one market and gives it more than one reimbursement and launch path. It also helps cushion demand swings in any single country.
Mochida collaboration on API
Amarin Corporation plc’s Mochida Pharmaceutical Co., Ltd. API deal widens Vascepa’s reach by giving icosapent ethyl more shots at new products and indications without Amarin funding every step alone. The tie-up also taps Mochida’s EPA-based know-how, which matters because Vascepa is built on purified eicosapentaenoic acid (EPA), a proven cardiovascular asset.
- More uses for one API
- Shared development burden
- EPA expertise adds speed
Established since 1989
Amarin Corporation plc was established in 1989 and rebranded in 1999, giving it 35+ years of operating history in pharmaceuticals. That long record supports know-how in drug development, regulation, and corporate continuity.
Its Dublin headquarters adds a stable legal and administrative base, which can help with governance and investor confidence. For a company still active in 2025/2026, that continuity matters.
- Founded in 1989
- Rebranded in 1999
- 35+ years of continuity
- Dublin-based HQ
VASCEPA Powers Amarin’s Focused Cardiovascular Growth
Amarin Corporation plc’s biggest strength is VASCEPA, the only prescription brand in its portfolio, which keeps the business focused on cardiovascular care. In 2024, Amarin Corporation plc reported about $220 million in net product revenue, showing the brand still drives the company. Its sales across the United States, Germany, Canada, Lebanon, and the UAE also reduce single-market risk. The Mochida Pharmaceutical Co., Ltd. API deal adds icosapent ethyl know-how and lowers development burden.
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Amarin Corporation plc’s business strategy
Editable Excel File
Provides a quick Amarin Corporation plc SWOT snapshot to relieve strategic planning pain points.
Reference Sources
Provides a concise, traceable list of authoritative sources (industry reports, filings, and datasets) to validate Amarin’s market, pricing, and competitive assumptions.
Weaknesses
1-product dependence
Amarin Corporation plc is highly exposed to VASCEPA, its only major revenue driver, so the business carries a clear single-asset risk. In fiscal 2024, Amarin reported about $0.2 billion in net revenue, and any sales slip, patent loss, or tougher competition can hit nearly the whole company at once. That concentration makes the weakness structural, not temporary.
Limited disease scope
Amarin Corporation plc remains tightly tied to cardiovascular care, with its business centered on VASCEPA and only one main therapeutic lane. That leaves it with fewer growth engines than diversified biopharma peers, and in 2025 it still had no broad portfolio to offset a slowdown in one category. One weak product trend can hit the whole company fast.
Small geographic base
Amarin Corporation plc has a small geographic base, with operations in only five countries or regions, which is far narrower than large pharma peers.
That limited footprint caps scale, reduces revenue diversification, and weakens bargaining power with payers and distributors.
In 2025, Amarin reported net revenue of about $219 million, and that concentration makes results more exposed to shifts in just a few markets.
Wholesale and specialty pharmacy reliance
Amarin Corporation plc still relies mainly on wholesale distributors and specialty pharmacies for Vascepa/Vazkepa, so a small number of intermediaries can shape sell-through, pricing, and access. That makes it more exposed to channel inventory swings and payer step edits or prior authorization rules, which can quickly pressure demand. One product, one narrow route to market.
- Wholesale and specialty channels dominate sales.
- Few intermediaries raise concentration risk.
- Inventory moves can distort quarterly revenue.
- Payer controls can slow patient starts.
Prescription-only adoption barrier
VASCEPA is prescription-only, so Amarin Corporation plc depends on physician scripts, payer approval, and patient copays. That makes uptake slower than OTC brands, where shoppers can buy on impulse. In 2025, that access hurdle still constrained growth versus easier-to-buy consumer health products.
- Prescription gate slows demand
- Reimbursement can block starts
- Growth needs physician adoption
Amarin’s Weak Spot: Too Much Reliance on One Drug
Amarin Corporation plc’s weakness is concentration: in 2025 it still depended almost entirely on VASCEPA/Vazkepa, with net revenue of about $219 million. It also relied on a narrow five-country footprint and a few wholesale and specialty channels, so payer edits, inventory swings, or slower scripts can move results fast. That leaves little buffer if access tightens.
| Weakness | 2025 data |
|---|---|
| Net revenue | $219 million |
| Geographic reach | 5 countries/regions |
| Core product mix | 1 main driver |
Preview Before You Purchase
Amarin Corporation plc Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.
The preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.
This is a real excerpt from the complete document. Once purchased, you’ll receive the full, editable version.
Opportunities
New indications from Vascepa API
Amarin Corporation plc’s collaboration with Mochida on Vascepa API opens new label uses that could reach beyond its current icosapent ethyl cardiovascular market. Vascepa’s core evidence base is strong: REDUCE-IT cut major adverse cardiovascular events by 25% relative risk, which supports broader follow-on indications.
Deeper penetration in cardiovascular care
Cardiovascular disease still causes about 17.9 million deaths a year, keeping lipid care a large chronic market. Amarin can raise specialist awareness around high triglycerides, which affect roughly 25% of U.S. adults, and drive more diagnosis in routine care. Better treatment uptake in existing markets can lift prescription volume for VASCEPA.
Geographic expansion beyond 5 markets
Amarin Corporation plc still sells in only 5 markets, so adding countries could widen the addressable base and cut reliance on the United States. In 2025, U.S. sales still drove most Vascepa revenue, so each new launch can diversify cash flow and slow concentration risk. Wider international rollout can also keep the brand relevant longer as U.S. growth matures.
Partner-led development model
Amarin Corporation plc’s Mochida partnership shows it can extend its asset base without taking on the full cost of local development. For a focused portfolio, that model can spread R&D spend, share market access work, and keep capital light.
- Lower development cash burn
- Faster market entry via partners
- Better fit for a narrow pipeline
That matters because partner-led deals can scale one asset across regions while Amarin keeps more of its own balance sheet flexible for the next program.
Omega-3 EPA platform extension
Amarin Corporation plc can extend its omega-3 EPA base beyond VASCEPA, since one molecule can support new doses, combos, and follow-on formulations. That is cheaper than building a new asset from zero, and it keeps the core EPA platform monetized; REDUCE-IT showed a 25% relative risk reduction in major CV events, which still anchors the value case.
- Reuse EPA chemistry across line extensions
- Lower R&D than a new platform
- Build on proven CV outcomes data
Amarin’s global VASCEPA growth runway is still wide open
Amarin Corporation plc can grow by expanding VASCEPA beyond 5 markets, using its Mochida deal to enter new countries with lighter capital needs. REDUCE-IT cut major CV events by 25% relative risk, and high triglycerides affect about 25% of U.S. adults, so diagnosis and uptake still have room to rise.
| Opportunity | Key data |
|---|---|
| New labels | 25% RRR in REDUCE-IT |
| Market expansion | 5 markets today |
| Demand growth | ~25% U.S. adults with high TG |
Threats
Competing lipid therapies
Amarin Corporation plc faces pressure from competing lipid therapies, including other triglyceride-lowering and cardiovascular-risk drugs that may have stronger clinical data, lower prices, or wider prescriber familiarity. In 2025, VASCEPA revenue remained under pressure as the cardiometabolic market stayed crowded, making share gains harder. That mix can limit pricing power and slow volume growth.
Pricing and reimbursement pressure
In 2025, Amarin Corporation plc still depended on payer coverage and pharmacy channel economics for VASCEPA sales. Insurers and health systems can tighten reimbursement for branded therapies, which cuts access and pushes higher rebates. Even if prescriptions stay flat, lower net pricing can still slow revenue growth.
Regulatory and label risk
Regulatory and label risk is a key threat for Amarin Corporation plc because every new indication or product claim needs FDA or ex-U.S. approval, and a delay can reset growth expectations. The company’s Vascepa franchise still depends on label breadth, so any negative ruling on efficacy, safety, or marketing claims can limit commercialization and hurt demand. Even a small labeling change can matter when one product carries most of the value.
Patent and exclusivity erosion
Patent and exclusivity erosion is a major threat for Amarin Corporation plc because a branded, single-product model can lose pricing power fast when protection weakens. In 2024, Amarin Corporation plc reported net product revenue of about $220 million, so even a modest share shift can hit sales hard. Once exclusivity fades, generics and weaker IP can quickly reshape the market and compress margins.
- Single-product risk is very high.
- IP loss can cut revenue fast.
- Generic entry drives price pressure.
Market concentration risk
Amarin Corporation plc is exposed to market concentration risk because its sales are still tied to a narrow set of countries and channels, so one policy shift, supply break, or weaker demand in a key market can hit revenue hard. International sales also add FX and compliance risk, and in its latest filings Amarin still reported losses, with 2025 visibility remaining limited outside its core markets.
- Few markets, high revenue concentration
- One disruption can move results fast
- FX and regulatory costs add pressure
Amarin’s Biggest Risks: VASCEPA Competition, Payer Pressure, and Patent Erosion
Amarin Corporation plc’s main threats are intense competition, payer pressure, and label risk around VASCEPA, which can cap growth even if prescribing holds. Its single-product model also leaves revenue exposed if patents weaken or generic entry accelerates. In 2024, net product revenue was about $220 million, showing how quickly small share losses can hit sales.
| Threat | Latest data |
|---|---|
| Net product revenue | About $220 million, 2024 |
| Core product | VASCEPA, single-product exposure |
| Risk areas | Competition, payer cuts, IP erosion |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.